In clinical trials, digital biomarkers are moving beyond isolated monitoring, attention is increasingly shifting toward digital phenotyping: integrating continuous, multimodal, real-world data into more scalable and clinically meaningful insights. In high-volume obesity and metabolic trials, tracking complex behavioral and physiological variables heavily increases patient and clinical site fatigue.
Building on the discussions initiated during Roche and HLTH’s virtual expert roundtable, this in-person session at HLTH Europe will explore what it will take to operationalize digital biomarkers at scale, particularly in metabolic diseases and obesity. It will address the core platform gaps and integration complexities that currently result in high participant dropout rates and siloed data hubs across the industry.
Join a select group of leaders from pharma, digital health, clinical development, and technology for a forward-looking discussion on how the ecosystem is evolving from exploratory digital signals toward more integrated, decision-grade approaches.
The conversation will focus on:
Why Digital Biomarkers Matter in Drug Development: Analyzing landmark operational success stories, such as digital endpoints in Parkinson's disease.
Digital Biomarkers in Obesity. What We Measure and Why: Dissect virtual roundtable conclusions around digital measures in obesity.
Operationalization of Digital Measurements: Reviewing the platform ecosystem for conducting obesity clinical trials and outlining strategies to radically simplify the patient and site user experience.
